Recently, Berry et al. [199] have demonstrated that ALKF1174L mutation potentiates the oncogenic activity of MYCN in NB by using a transgenic mouse model that overexpresses the ALKF1174L and MYCN genes in the neural crest under the control of the rat tyrosine hydroxilase promoter. This evidence concerns the gene MYCN and neuroblastoma.